Putting Patients First Blog

APRIL 14, 2023

Driven by the work of the Food and Drug Administration on patient-focused drug development (PFDD), many companies in the biopharmaceutical community have devoted significant resources to better understand patient populations and are working to bring to market products that best suit their needs. Sincerely, Randall L.

Drug Pricing 40

Drug Pricing Drug Development Documentation Communication 40

Viseven

SEPTEMBER 18, 2024

When COVID hit, the urgent need to accelerate drug development meant shrinking timelines from years to months, with no room for compromises on quality. This innovative approach has brought more than 40 successful drug discovery projects to AstraZeneca. By the end of 2026, the company will be able to analyze two million genomes.

Communication 52

Communication Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

FDA Law Blog: Biosimilars

OCTOBER 13, 2024

We have heard over and over again how the potential for a priority review voucher has allowed small companies with limited resources to invest in the development of drugs for rare pediatric diseases. No rare pediatric disease vouchers could be awarded even to designated applications after September 30, 2026.

Documentation 64

Documentation Drug Development 64